ADMA Biologics, Inc. (ADMA) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 1 Strong Buy, 7 Buy, 1 Hold.
The consensus price target is $16.00 (low: $14.00, high: $18.00), representing an upside of 52.5% from the current price $10.49.
Analysts estimate Earnings Per Share (EPS) of $0.51 and revenue of $0.42B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $0.85 vs est $0.51 (beat +65.6%). 2025: actual $0.62 vs est $0.59 (beat +6%). Analyst accuracy: 77%.
ADMA Stock — 12-Month Price Forecast
$16.00
▲ +52.53% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for ADMA Biologics, Inc., the average price target is $16.00, with a high forecast of $18.00, and a low forecast of $14.00.
The average price target represents a +52.53% change from the last price of $10.49.
Highest Price Target
$18.00
Average Price Target
$16.00
Lowest Price Target
$14.00
ADMA Analyst Ratings
Buy
Based on 9 analysts giving stock ratings to ADMA Biologics, Inc. in the past 3 months
EPS Estimates — ADMA
77%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.85
vs Est $0.51
▲ 39.6% off
2025
Actual $0.62
vs Est $0.59
▲ 5.6% off
Profitability Outlook
Company is profitable but with thin earnings per share. EPS trend is declining.
Revenue Estimates — ADMA
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.426B
vs Est $0.422B
▲ 1.1% off
2025
Actual $0.510B
vs Est $0.511B
▼ 0.1% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
